| Name | MPTP hydrochloride |
| Description | MPTP hydrochloride is a precursor of MPP+, a dopamine neurotoxin with blood-brain barrier permeability. MPTP hydrochloride is toxic to dopaminergic neurons, which can lead to Parkinson's disease, and is widely used in the construction of animal models of Parkinson's disease. |
| In vitro | METHODS: Human neuroblastoma cells M17 were treated with MPTP hydrochloride (1-50 μM) for 48 h. The expression levels of target proteins were detected by Western Blot.
RESULTS: MPTP hydrochloride promoted Tau protein phosphorylation in M17 cells. [1]
METHODS: Neuroblastoma cell N2AB-1 and glioma cell C6 were treated with MPTP hydrochloride (0.33-33.7 μM) for 24 h, and the growth curves were examined.
RESULTS: MPTP hydrochloride did not affect the cell number of actively growing N2AB-1 or C6 cells. [2] |
| In vivo | METHODS: To construct a subacute Parkinson's model, MPTP hydrochloride (30 mg/kg in 0.9% saline) was administered intraperitoneally to C57BL/6 mice once daily for five days.
RESULTS: Subacute MPTP hydrochloride treatment did not cause significant motor deficits, although the dopaminergic system was severely impaired. mPTP hydrochloride significantly increased the level of α-synuclein and the number of astrocytes in the striatum and disrupted the blood-brain barrier in the substantia nigra pars compacta. [3]
METHODS: To study the effects of different models on the behavior and pathology of a mouse model of Parkinson's disease, MPTP hydrochloride was used intraperitoneally to construct a subacute model group and a chronic model group. In the subacute model group, MPTP hydrochloride (30 mg/kg) was administered once daily for ten days. In the chronic model group, MPTP hydrochloride (30 mg/kg) was injected once every 3.5 days for five weeks for ten times.
RESULTS: In the MPTP hydrochloride-induced subacute Parkinson's disease mouse model, there was a small loss of dopaminergic neurons in the midbrain, but there was no effect on the behavior.The MPTP hydrochloride-induced chronic Parkinson's disease mouse model lost a large number of dopaminergic neurons, which was accompanied by anxiety-like behaviors in addition to motor dysfunction. [4] |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice./Shipping at ambient temperature. |
| Solubility Information | H2O : 10 mg/mL (47.68 mM), Sonication is recommended.
DMSO : 5 mg/mL (23.84 mM), Sonication is recommended.
|
| Keywords | penetrant | Parkinson's | neurotoxin | MPTP Hydrochloride | MPTP hydrochloride | MPTP | Inhibitor | inhibit | DopamineReceptor | Dopamine Receptor | Dopamine | Disease | brain | Apoptosis |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Flubendazole | Cysteamine hydrochloride | L-Glutamic acid monosodium salt monohydrate | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | L-Glutamic acid | Tributyrin | L-Ascorbic acid sodium salt | Alginic acid |
| Related Compound Libraries | Ferroptosis Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Neuronal Signaling Compound Library | Anti-Alzheimer's Disease Compound Library | Membrane Protein-targeted Compound Library | Neurotransmitter Receptor Compound Library | Endocrinology-Hormone Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library |
United States
